HealthWarehouse.com Q1 sales fall after FDA ends GLP-1 shortage

HealthWarehouse.com

11/05/2026 21:19

Overview

U.S. healthcare e-commerce platform's Q1 net sales fell 58% after FDA ended GLP-1 shortage

Company posted Q1 net loss and negative adjusted EBITDA as compounded prescription sales declined

Gross margin improved to 52.1% as B2B prescription sales declined and OTC sales increased

Outlook

HealthWarehouse.com expects new partnerships and business units to support growth opportunities

Company continues to invest in proprietary technology to enhance customer experience and scalability

HealthWarehouse.com expects partnership with healthwords.ai to accelerate operational efficiency and growth

Result Drivers

FDA REGULATORY CHANGE - Co said Q1 sales decline was mainly due to the FDA ending allowance for compounded GLP-1 prescriptions, reducing B2B prescription revenue

OTC SALES GROWTH - Co said OTC net sales rose 61.9% year-over-year, mainly from increased marketplace sales

TECHNOLOGY AND PARTNERSHIPS - Co said it is investing in proprietary technology and formed a new AI partnership to support growth and operational efficiency

Company press release: ID:nBw3VNRlla

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
$6.3 mln
Q1 Gross Profit
$3.3 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)